Company Filing History:
Years Active: 2017
Title: Hsu-Chung Gabriel Chen: Innovator in Porcine Circovirus Research
Introduction
Hsu-Chung Gabriel Chen is a prominent inventor based in Taipei, Taiwan. He has made significant contributions to the field of veterinary medicine, particularly in the development of immunogenic compositions for porcine circovirus type 2 (PCV2). With a total of 2 patents, his work is crucial for enhancing the health and productivity of swine.
Latest Patents
Hsu-Chung Gabriel Chen's latest patents include innovative solutions for combating porcine circovirus type 2. The first patent focuses on a novel PCV2 strain, along with immunogenic compositions and test kits for its application. This invention aims to provide effective tools for diagnosing and managing PCV2 infections in pigs. The second patent involves a PCV2 subunit vaccine that includes an antigenic peptide derived from the PCV2 open reading frame 2 (ORF2). This vaccine is designed to stimulate an immune response while minimizing the presence of arginine-rich peptides, enhancing its efficacy.
Career Highlights
Hsu-Chung Gabriel Chen is associated with Sbc Virbac Limited, where he continues to advance research in veterinary immunology. His work has been instrumental in developing solutions that address significant health challenges in the swine industry. His innovative approaches have garnered attention and respect within the scientific community.
Collaborations
Hsu-Chung Gabriel Chen collaborates with notable colleagues such as Tsun-Yung Kuo and Shu-Hsiang Yang. Together, they work on various projects aimed at improving animal health through innovative research and development.
Conclusion
Hsu-Chung Gabriel Chen is a key figure in the field of veterinary medicine, particularly in the fight against porcine circovirus type 2. His patents and ongoing research contribute significantly to the health and welfare of swine, showcasing the importance of innovation in this sector.